ABSTRACT
OBJECTIVE: Buprenorphine has a partial morphine-agonist pharmacological profile. It is proposed as alternative to methadone in opiate drug addicts with greater safety of use and less cost in terms of public health. The aim of this study was to determine the clinical factors of response to this molecule. METHOD: The study was conducted in 73 patients treated for 3 months with adaptable doses. Mean dose was 8.5 mg/d (range: 3 to 16 mg/d). Response to treatment was defined as: still in the study at 3 months and absence of opiates in 75% of urinary samples over the past month. RESULTS: Forty-eight patients responded and 25 did not. The determinating clinical variables of response were: opiate drug addiction less than 10 years, high score on the Addiction Severity Index (ASI), absence of depression according to the Minnesota Multiphasic Personality Inventory (MMPI) and low rate of disinhibition on Zukerman's sensation seeking scale. Conversely, the dose of buprenorphine within the limits specified in the Marketing Authorisation did not intervene in the response. CONCLUSION: In view of its partial agonist effect, administration of buprenorphine must be reserved for patients addicted to opiates for less than 10 years, non-depressive and with low disinhibition on Zukerman's scale.
Subject(s)
Buprenorphine/therapeutic use , Heroin Dependence/drug therapy , Narcotics/therapeutic use , Adult , Female , Humans , Male , Prognosis , Prospective StudiesABSTRACT
In 1974, rapid cycling bipolar disorder has been defined by Dunner and Fieve as four or more episodes of depression or mania per year. Twenty year later, this definition appeared for the first line in an international classification of mental disorders in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders. The rapid cycling phenomenon has been since studied with new adapted modified criteria taking into account different duration of affective episodes which characterise rapid cycling. Rapid cycling is associated with a low prophylactic efficacy of lithium and often represents a difficult approach for the clinician. Clinical aspects, influence of antidepressants associated with acceleration of cycles and possible therapeutic trials including non pharmaceutical treatment are discussed.
Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder , Periodicity , Bipolar Disorder/diagnosis , Bipolar Disorder/parasitology , Bipolar Disorder/therapy , Combined Modality Therapy , Humans , Psychiatric Status Rating ScalesABSTRACT
Depressive syndromes are very frequent in drug-addicted patients. Their study is particularly difficult on account of the toxic intake which disturbs the clinical analysis. Methadone has improved our understanding of these pathologies. In fact, methadone permits treatment of some depressive disorders typically linked to addiction, such as a motivational symptoms and depressive mood following intoxication. It brings to the fore the other mood disorders which are often associated with drug intake.